These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26830393)

  • 21. Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome - NO.
    Scalfari A
    Mult Scler; 2015 Oct; 21(11):1371-4. PubMed ID: 26438304
    [No Abstract]   [Full Text] [Related]  

  • 22. Secondary progressive multiple sclerosis: current knowledge and future challenges.
    Rovaris M; Confavreux C; Furlan R; Kappos L; Comi G; Filippi M
    Lancet Neurol; 2006 Apr; 5(4):343-54. PubMed ID: 16545751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The natural history of multiple sclerosis.
    Deshpande R; Kremenchutzky M; Rice GP
    Adv Neurol; 2006; 98():1-15. PubMed ID: 16400823
    [No Abstract]   [Full Text] [Related]  

  • 24. Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis.
    Sotgiu S; Mameli G; Serra C; Zarbo IR; Arru G; Dolei A
    Mult Scler; 2010 Oct; 16(10):1248-51. PubMed ID: 20685761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of patient-reported outcome measures in multiple sclerosis.
    Schäffler N; Schönberg P; Stephan J; Stellmann JP; Gold SM; Heesen C
    Acta Neurol Scand; 2013 Aug; 128(2):114-21. PubMed ID: 23398571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re: Yianni et al., Globus pallidus internus deep brain stimulation for dystonic conditions: a prospective audit.
    Quinn NP; Bhatia K
    Mov Disord; 2004 Jan; 19(1):114. PubMed ID: 14743373
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical course and prognosis of 27 patients with childhood onset multiple sclerosis in Japan.
    Shiraishi K; Higuchi Y; Ozawa K; Hao Q; Saida T
    Brain Dev; 2005 Apr; 27(3):224-7. PubMed ID: 15737705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge.
    Jacobsen CO; Farbu E
    Acta Neurol Scand Suppl; 2014; (198):32-6. PubMed ID: 24588504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of symptoms in multiple sclerosis.
    Schwendimann RN
    Neurol Res; 2006 Apr; 28(3):306-15. PubMed ID: 16687058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.
    Paling D; Solanky BS; Riemer F; Tozer DJ; Wheeler-Kingshott CA; Kapoor R; Golay X; Miller DH
    Brain; 2013 Jul; 136(Pt 7):2305-17. PubMed ID: 23801742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment modification in multiple sclerosis: classifications, alternatives, and the outcomes].
    Cendrowski W
    Neurol Neurochir Pol; 2007; 41(4):365-8. PubMed ID: 18027457
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical outcomes assessment in multiple sclerosis.
    Rudick R; Antel J; Confavreux C; Cutter G; Ellison G; Fischer J; Lublin F; Miller A; Petkau J; Rao S; Reingold S; Syndulko K; Thompson A; Wallenberg J; Weinshenker B; Willoughby E
    Ann Neurol; 1996 Sep; 40(3):469-79. PubMed ID: 8797541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural history of multiple sclerosis: risk factors and prognostic indicators.
    Vukusic S; Confavreux C
    Curr Opin Neurol; 2007 Jun; 20(3):269-74. PubMed ID: 17495619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An assessment of plasma exchange in progressive multiple sclerosis.
    Weiner HL
    Neurology; 1985 Mar; 35(3):320-2. PubMed ID: 3883234
    [No Abstract]   [Full Text] [Related]  

  • 36. Predictors of the physical impact of Multiple Sclerosis following community-based, exercise trial.
    Kehoe M; Saunders J; Jakeman P; Coote S
    Mult Scler; 2015 Apr; 21(5):590-8. PubMed ID: 25209170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of multiple sclerosis symptoms across lifespan: data from the NARCOMS Registry.
    Fox RJ; Bacon TE; Chamot E; Salter AR; Cutter GR; Kalina JT; Kister I
    Neurodegener Dis Manag; 2015; 5(6 Suppl):3-10. PubMed ID: 26611264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Conclusion].
    Vermersch P
    Rev Neurol (Paris); 2009 Mar; 165 Suppl 4():S180-1. PubMed ID: 19361685
    [No Abstract]   [Full Text] [Related]  

  • 39. Are we in need of NEDA?
    Freedman MS
    Mult Scler; 2016 Jan; 22(1):5-6. PubMed ID: 26552731
    [No Abstract]   [Full Text] [Related]  

  • 40. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
    Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T
    J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.